U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Non-Hodgkin Lymphoma

MedGen UID:
163158
•Concept ID:
C0854867
•
Neoplastic Process
Synonyms: Non-Hodgkin's Lymphoma Refractory; NonHodgkin's Lymphoma Refractory; Refractory Non-Hodgkin's Lymphoma

Definition

A non-Hodgkin lymphoma which does not respond to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Non-Hodgkin Lymphoma

Professional guidelines

PubMed

CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma.
Larson SM, Walthers CM, Ji B, Ghafouri SN, Naparstek J, Trent J, Chen JM, Roshandell M, Harris C, Khericha M, Schweppe T, Berent-Maoz B, Gosliner SB, Almaktari A, Ceja MA, Allen-Auerbach MS, Said J, Nawaly K, Mead M, de Vos S, Young PA, Oliai C, Schiller GJ, Timmerman JM, Ribas A, Chen YY
Cancer Discov 2023 Mar 1;13(3):580-597. doi: 10.1158/2159-8290.CD-22-0964. PMID: 36416874Free PMC Article
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy.
Carreau NA, Armand P, Merryman RW, Advani RH, Spinner MA, Herrera AF, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Nathan S, Karmali R, Torka P, David K, Lansigan F, Persky D, Godfrey J, Chavez JC, Xia Y, Diefenbach C
Br J Haematol 2020 Oct;191(1):44-51. Epub 2020 May 19 doi: 10.1111/bjh.16756. PMID: 32430944
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.
Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, Diggelmann S, Limani F, Schlenker R, Hüsser T, Richter W, Bray-French K, Hinton H, Giusti AM, Freimoser-Grundschober A, Lariviere L, Neumann C, Klein C, Umaña P
Clin Cancer Res 2018 Oct 1;24(19):4785-4797. Epub 2018 May 1 doi: 10.1158/1078-0432.CCR-18-0455. PMID: 29716920

Recent clinical studies

Etiology

Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma.
Chu Y, Gardenswartz A, Diorio C, Marks LJ, Lowe E, Teachey DT, Cairo MS
Best Pract Res Clin Haematol 2023 Mar;36(1):101442. Epub 2023 Feb 2 doi: 10.1016/j.beha.2023.101442. PMID: 36907635
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy.
Carreau NA, Armand P, Merryman RW, Advani RH, Spinner MA, Herrera AF, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Nathan S, Karmali R, Torka P, David K, Lansigan F, Persky D, Godfrey J, Chavez JC, Xia Y, Diefenbach C
Br J Haematol 2020 Oct;191(1):44-51. Epub 2020 May 19 doi: 10.1111/bjh.16756. PMID: 32430944
Response to hyperfractionated accelerated radiotherapy in chemotherapy-refractory non-Hodgkin lymphoma.
Kim DW, Lee G, Lee H, Mahal AR, Lam MB, Ng AK
Leuk Lymphoma 2020 Jun;61(6):1428-1434. Epub 2020 Feb 26 doi: 10.1080/10428194.2020.1719096. PMID: 32102580
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, Press OW, Salles G, Tilly H, Chen AI, Assouline S, Cheson BD, Dreyling M, Hagenbeek A, Zinzani PL, Jones S, Cheng J, Lu D, Penuel E, Hirata J, Wenger M, Chu YW, Sharman J
Lancet Haematol 2019 May;6(5):e254-e265. Epub 2019 Mar 29 doi: 10.1016/S2352-3026(19)30026-2. PMID: 30935953
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF
J Clin Oncol 2017 Mar 10;35(8):826-833. Epub 2017 Jan 17 doi: 10.1200/JCO.2016.70.4320. PMID: 28095146Free PMC Article

Diagnosis

Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor - a retrospective, single center study.
Ben Barouch S, Bhella S, Kridel R, Kukreti V, Prica A, Crump M, Kuruvilla J
Leuk Lymphoma 2022 Aug;63(8):1879-1886. Epub 2022 Mar 9 doi: 10.1080/10428194.2022.2047674. PMID: 35263209
MTX-HOPE is a low-dose salvage chemotherapy for aged patients with relapsed or refractory non-Hodgkin lymphoma.
Suzuki M, Tsunoda S, Koyama D, Ikeda S, Sukegawa M, Hojo H, Ohta M
J Clin Exp Hematop 2021 Mar 18;61(1):22-28. Epub 2021 Feb 6 doi: 10.3960/jslrt.20051. PMID: 33551437Free PMC Article
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma.
Tong C, Zhang Y, Liu Y, Ji X, Zhang W, Guo Y, Han X, Ti D, Dai H, Wang C, Yang Q, Liu W, Wang Y, Wu Z, Han W
Blood 2020 Oct 1;136(14):1632-1644. doi: 10.1182/blood.2020005278. PMID: 32556247Free PMC Article
Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use.
Hughes ME, Landsburg DJ, Rubin DJ, Schuster SJ, Svoboda J, Gerson JN, Namoglu E, Nasta SD
Clin Lymphoma Myeloma Leuk 2019 Dec;19(12):791-798. Epub 2019 Sep 28 doi: 10.1016/j.clml.2019.09.612. PMID: 31648953
Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies.
Witkowska M, Smolewski P, Robak T
Expert Opin Investig Drugs 2018 Feb;27(2):171-177. Epub 2018 Jan 15 doi: 10.1080/13543784.2018.1427730. PMID: 29323537

Therapy

CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma.
Larson SM, Walthers CM, Ji B, Ghafouri SN, Naparstek J, Trent J, Chen JM, Roshandell M, Harris C, Khericha M, Schweppe T, Berent-Maoz B, Gosliner SB, Almaktari A, Ceja MA, Allen-Auerbach MS, Said J, Nawaly K, Mead M, de Vos S, Young PA, Oliai C, Schiller GJ, Timmerman JM, Ribas A, Chen YY
Cancer Discov 2023 Mar 1;13(3):580-597. doi: 10.1158/2159-8290.CD-22-0964. PMID: 36416874Free PMC Article
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Chávez JC, Duell J, Rosenwald A, Crombie JL, Ufkin M, Li J, Zhu M, Ambati SR, Chaudhry A, Lowy I, Topp MS
Lancet Haematol 2022 May;9(5):e327-e339. Epub 2022 Apr 1 doi: 10.1016/S2352-3026(22)00072-2. PMID: 35366963Free PMC Article
Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma.
Bröske AE, Korfi K, Belousov A, Wilson S, Ooi CH, Bolen CR, Canamero M, Alcaide EG, James I, Piccione EC, Carlile DJ, Dimier N, Umaña P, Bacac M, Weisser M, Dickinson M
Blood Adv 2022 Feb 8;6(3):1025-1037. doi: 10.1182/bloodadvances.2021005954. PMID: 34941996Free PMC Article
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma.
Tong C, Zhang Y, Liu Y, Ji X, Zhang W, Guo Y, Han X, Ti D, Dai H, Wang C, Yang Q, Liu W, Wang Y, Wu Z, Han W
Blood 2020 Oct 1;136(14):1632-1644. doi: 10.1182/blood.2020005278. PMID: 32556247Free PMC Article
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.
Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, Diggelmann S, Limani F, Schlenker R, Hüsser T, Richter W, Bray-French K, Hinton H, Giusti AM, Freimoser-Grundschober A, Lariviere L, Neumann C, Klein C, Umaña P
Clin Cancer Res 2018 Oct 1;24(19):4785-4797. Epub 2018 May 1 doi: 10.1158/1078-0432.CCR-18-0455. PMID: 29716920

Prognosis

Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma.
Chu Y, Gardenswartz A, Diorio C, Marks LJ, Lowe E, Teachey DT, Cairo MS
Best Pract Res Clin Haematol 2023 Mar;36(1):101442. Epub 2023 Feb 2 doi: 10.1016/j.beha.2023.101442. PMID: 36907635
Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma.
Bröske AE, Korfi K, Belousov A, Wilson S, Ooi CH, Bolen CR, Canamero M, Alcaide EG, James I, Piccione EC, Carlile DJ, Dimier N, Umaña P, Bacac M, Weisser M, Dickinson M
Blood Adv 2022 Feb 8;6(3):1025-1037. doi: 10.1182/bloodadvances.2021005954. PMID: 34941996Free PMC Article
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma.
Tong C, Zhang Y, Liu Y, Ji X, Zhang W, Guo Y, Han X, Ti D, Dai H, Wang C, Yang Q, Liu W, Wang Y, Wu Z, Han W
Blood 2020 Oct 1;136(14):1632-1644. doi: 10.1182/blood.2020005278. PMID: 32556247Free PMC Article
Response to hyperfractionated accelerated radiotherapy in chemotherapy-refractory non-Hodgkin lymphoma.
Kim DW, Lee G, Lee H, Mahal AR, Lam MB, Ng AK
Leuk Lymphoma 2020 Jun;61(6):1428-1434. Epub 2020 Feb 26 doi: 10.1080/10428194.2020.1719096. PMID: 32102580
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, Press OW, Salles G, Tilly H, Chen AI, Assouline S, Cheson BD, Dreyling M, Hagenbeek A, Zinzani PL, Jones S, Cheng J, Lu D, Penuel E, Hirata J, Wenger M, Chu YW, Sharman J
Lancet Haematol 2019 May;6(5):e254-e265. Epub 2019 Mar 29 doi: 10.1016/S2352-3026(19)30026-2. PMID: 30935953

Clinical prediction guides

CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma.
Larson SM, Walthers CM, Ji B, Ghafouri SN, Naparstek J, Trent J, Chen JM, Roshandell M, Harris C, Khericha M, Schweppe T, Berent-Maoz B, Gosliner SB, Almaktari A, Ceja MA, Allen-Auerbach MS, Said J, Nawaly K, Mead M, de Vos S, Young PA, Oliai C, Schiller GJ, Timmerman JM, Ribas A, Chen YY
Cancer Discov 2023 Mar 1;13(3):580-597. doi: 10.1158/2159-8290.CD-22-0964. PMID: 36416874Free PMC Article
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Chávez JC, Duell J, Rosenwald A, Crombie JL, Ufkin M, Li J, Zhu M, Ambati SR, Chaudhry A, Lowy I, Topp MS
Lancet Haematol 2022 May;9(5):e327-e339. Epub 2022 Apr 1 doi: 10.1016/S2352-3026(22)00072-2. PMID: 35366963Free PMC Article
Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma.
Bröske AE, Korfi K, Belousov A, Wilson S, Ooi CH, Bolen CR, Canamero M, Alcaide EG, James I, Piccione EC, Carlile DJ, Dimier N, Umaña P, Bacac M, Weisser M, Dickinson M
Blood Adv 2022 Feb 8;6(3):1025-1037. doi: 10.1182/bloodadvances.2021005954. PMID: 34941996Free PMC Article
Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use.
Hughes ME, Landsburg DJ, Rubin DJ, Schuster SJ, Svoboda J, Gerson JN, Namoglu E, Nasta SD
Clin Lymphoma Myeloma Leuk 2019 Dec;19(12):791-798. Epub 2019 Sep 28 doi: 10.1016/j.clml.2019.09.612. PMID: 31648953
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF
J Clin Oncol 2017 Mar 10;35(8):826-833. Epub 2017 Jan 17 doi: 10.1200/JCO.2016.70.4320. PMID: 28095146Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...